CA3222535A1 - Treatment or prevention of ischaemia reperfusion injury - Google Patents

Treatment or prevention of ischaemia reperfusion injury Download PDF

Info

Publication number
CA3222535A1
CA3222535A1 CA3222535A CA3222535A CA3222535A1 CA 3222535 A1 CA3222535 A1 CA 3222535A1 CA 3222535 A CA3222535 A CA 3222535A CA 3222535 A CA3222535 A CA 3222535A CA 3222535 A1 CA3222535 A1 CA 3222535A1
Authority
CA
Canada
Prior art keywords
composition
use according
salt
malonate
reperfusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3222535A
Other languages
English (en)
French (fr)
Inventor
Thomas Krieg
Michael P Murphy
Hiran A PRAG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge Enterprise Ltd
Original Assignee
Cambridge Enterprise Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Enterprise Ltd filed Critical Cambridge Enterprise Ltd
Publication of CA3222535A1 publication Critical patent/CA3222535A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3222535A 2021-06-16 2022-06-08 Treatment or prevention of ischaemia reperfusion injury Pending CA3222535A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2108594.9A GB202108594D0 (en) 2021-06-16 2021-06-16 Treatment or prevention of ischaemia reperfusion injury
GB2108594.9 2021-06-16
PCT/GB2022/051436 WO2022263792A1 (en) 2021-06-16 2022-06-08 Treatment or prevention of ischaemia reperfusion injury

Publications (1)

Publication Number Publication Date
CA3222535A1 true CA3222535A1 (en) 2022-12-22

Family

ID=76954409

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3222535A Pending CA3222535A1 (en) 2021-06-16 2022-06-08 Treatment or prevention of ischaemia reperfusion injury

Country Status (7)

Country Link
US (1) US20240252457A1 (https=)
EP (1) EP4355315A1 (https=)
JP (1) JP2024522767A (https=)
AU (1) AU2022294208A1 (https=)
CA (1) CA3222535A1 (https=)
GB (1) GB202108594D0 (https=)
WO (1) WO2022263792A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201918022D0 (en) * 2019-12-09 2020-01-22 Cambridge Entpr Ltd Treatment or prevention of Ischaemic Stroke Reperfusion Injury
WO2025125766A1 (en) 2023-12-12 2025-06-19 Cambridge Enterprise Limited Treatment or prevention of ischaemia reperfusion injury

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201411937D0 (en) * 2014-07-03 2014-08-20 Medical Res Council Succinate dehydrogenase inhibitors (SDH's)
EP3416634A4 (en) * 2016-02-15 2019-10-09 Artyomov, Maxim IMMUNOMODULATORY AGENTS AND METHOD FOR USE THEREOF
GB201918022D0 (en) * 2019-12-09 2020-01-22 Cambridge Entpr Ltd Treatment or prevention of Ischaemic Stroke Reperfusion Injury

Also Published As

Publication number Publication date
GB202108594D0 (en) 2021-07-28
JP2024522767A (ja) 2024-06-21
US20240252457A1 (en) 2024-08-01
WO2022263792A1 (en) 2022-12-22
EP4355315A1 (en) 2024-04-24
AU2022294208A1 (en) 2024-01-25

Similar Documents

Publication Publication Date Title
Bochelen et al. Calcineurin inhibitors FK506 and SDZ ASM 981 alleviate the outcome of focal cerebral ischemic/reperfusion injury
JP2008525468A (ja) ポストコンディショニング臓器保護作用を増強する治療補助薬
US20240252457A1 (en) Treatment or Prevention of Ischaemia Reperfusion Injury
Sheng et al. Neuroprotective efficacy from a lipophilic redox-modulating Mn (III) N-Hexylpyridylporphyrin, MnTnHex-2-PyP: rodent models of ischemic stroke and subarachnoid hemorrhage
Fu et al. Recombinant human erythropoietin preconditioning attenuates liver ischemia reperfusion injury through the phosphatidylinositol-3 kinase/AKT/endothelial nitric oxide synthase pathway
KR20170005497A (ko) 관상과 동맥의 동맥류성 지주하막출혈의 치료를 위한 조성물 및 방법
EP4072522B1 (en) Malonate salt for use in the treatment or prevention of ischaemic stroke reperfusion injury
US5512573A (en) Use of phthaloylhydrazide derivatives as anti-hypoxic and defensive agents
US20140322315A1 (en) Cysteamine and/or cystamine for treating ischemic injury
JP2018508479A (ja) 虚血性脳卒中を予防・治療するための薬物の調製におけるビフェノールの使用
TWI464147B (zh) 吲哚氫胺酸和吲哚啉氫胺酸於治療心臟衰竭或神經損傷的用途
US20220296579A1 (en) Compositions and methods for providing cardioprotective effects
JP2022514537A (ja) 急性心房細動の処置のためのサルカルディン投与
KR20180086431A (ko) L-오르니틴 페닐아세테이트의 제제
AU2010277725B2 (en) Otamixaban for treatment of elderly and renal impaired non-ST elevation myocardial infarction patients
WO2025125766A1 (en) Treatment or prevention of ischaemia reperfusion injury
CN113677202B (zh) 靶向线粒体的异缩酮/isolevuglandin清除剂
WO2020028745A1 (en) Methods for reducing abnormal scar formation
WO2006117165A2 (en) Means and methods for the treatment of head injuries and stroke
CN113368106B (zh) 艾托莫德用于防治特发性肺纤维化的药物中的用途
WO2009091134A2 (en) Pharmaceutical composition for sepsis and septic shock
CZ20023095A3 (cs) Farmaceutický prostředek
US9872882B2 (en) Aurantiamide dipeptide derivatives for treatment or prevention of angiogenesis-related diseases
KR20150047515A (ko) 관상동맥 우회로 이식술이 예정된 환자의 st 비상승 급성 관상동맥 증후군 치료에 사용되는 오타믹사반
JPWO2006035673A1 (ja) 虚血性心臓傷害の新保護法

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250602

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250602